Pfizer works to lower manufacturing costs

"Profitability comes from low-cost manufacturing," says Jean-Michel Halfon, Pfizer president for emerging markets. "Low-cost solutions developed in emerging markets could be useful everywhere. We're working on it." Article

Suggested Articles

Dr. Reddy’s says it has been told the FDA will not take regulatory action at its sterile formulations plant in Duvvada, Visakhapatnam.

The end is near for a GlaxoSmithKline OTC plant in Pennsylvania and its 260 employees. In fact, it has a date. 

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.